Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

تقرير يلقي الضوء على تأثير الأزمة السورية على المستشفيات الحكومية


The impact of the Syrian crisis on Lebanon has been profound particularly in the healthcare sector. The influx of Syrian refugees has strained the public hospitals and their ability to respond to the crisis, resulting in:
  • An increased demand for healthcare services;
  • An increase in unpaid health services to refugees;
  • A sharp rise in communicable diseases and emergence of new diseases in Lebanon;
  • Increased risks of epidemics such as water-borne diseases, measles, and tuberculosis 1.
Neither United Nations High Commissioner of Refugees (UNHCR) nor other Non-Governmental Organizations (NGO) was able to meet the required level of funding to provide refugees with an acceptable level of secondary and tertiary healthcare services. They, therefore, decided to change their model of response in terms of healthcare support to Syrian refugees. As of 2014, UNHCR started covering 75% instead 85% of the hospitalization cost, leaving the patient with the remaining share of 25% to be paid out of pocket or by a third party. The healthcare referrals covered by UNHCR are limited to deliveries and life-threatening emergencies 2.

Hospitals are overburdened with Syrian patients who are unable to pay their part of the bill (increased to 25% of their total hospital fees) as well as patients whose hospitalizations are not subsidized at all. Some hospitals have put in place strategies to recover as much of the 25% as possible (deposits, retaining IDs/corpses, inflating bills). Referral of uncovered Syrian patients with complicated morbidities to public hospitals has become a common practice by private hospitals.

Overwhelmed by the high demand of healthcare by Syrian refugees, public hospitals end up treating patients without any specific reimbursement scheme thus creating a huge financial burden. This burden adds up to the existing difficult financial situation of public hospitals, putting the whole healthcare sector under stress. Public hospitals are restrained from completing their mission and incapable of providing healthcare services neither to Syrians refugees nor to Lebanese citizens...
    3
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA02 ESTECINA 200MG G Ciprofloxacine (lactate) - 200mg/100ml 200mg/100ml Injectable solution 32,190,251 L.L
A08AB01 ELIZA 120 G Orlistat - 120mg 120mg Capsule 1,167,223 L.L
A08AB01 ELIZASLIM 120 G Orlistat - 120mg 120mg Capsule 1,167,223 L.L
D10AD51 ERYLIK G Tretinoin - 0.025%, Erythromycin - 4% Gel 378,964 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 2.5mg 2.5mg Tablet L.L
B03AB ENRICH N G Iron trivalent (hydroxide polymaltose complex) - 156.25mg/5ml Syrup 279,519 L.L
J01MA12 EVOXIL HELLAS G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 959,504 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 5mg 5mg Tablet L.L
B03AB05 ENRICH N G Iron trivalent (hydroxide polymaltose complex) - 50mg/ml 50mg/ml Drops 459,594 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 10mg 10mg Tablet L.L
A11CC05 EURO D 10000 IU G Vitamin D3 - 10,000IU 10,000IU Capsule 993,100 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 5mg 5mg Tablet 73,160,279 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 5mg 5mg Tablet 89,386,347 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 1mg 1mg Tablet, coated L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 0.5mg 0.5mg Tablet, coated L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 10mg 10mg Tablet 91,752,764 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 10mg 10mg Tablet 124,701,632 L.L
B03AD EURO-FER CF G Folic acid - 0.5mg, Vitamin C - 200mg, Ferrous fumarate - 300mg Capsule 706,861 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 2.5mg 2.5mg Tablet 57,802,039 L.L
A02BC05 ESO TAD G Esomeprazole - 20mg 20mg Capsule, hard, gastro-resistant 299,677 L.L
D10AF02 ERYTHROMYCIN 1.5 % G Erythromycin - 15mg/ml 1.50% Solution 501,701 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 2.5mg 2.5mg Tablet 52,290,378 L.L
A02BC05 ESOCAP-UBSA G Esomeprazole - 20mg 20mg Capsule 511,940 L.L
A11CC05 EURO D HP 50.000 IU G Vitamin D3 - 50,000IU 50,000IU Capsule 1,432,536 L.L
R06AX22 EBASTINE ARROW G Ebastine - 10mg 10mg Tablet, coated 524,099 L.L
A02BC05 ESOMEP G Esomeprazole - 20mg 20mg Tablet, gastroresistant 432,092 L.L
R06AX26 EXOFEN G Fexofenadine HCl - 120mg 120mg Tablet, film coated 287,582 L.L
A02BC05 ESOMEPRAZOLE ARROW G Esomeprazole - 20mg 20mg Capsule, gastro-resistant 366,869 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 5mg 5mg Tablet L.L
A02BC05 ESOMEPRAZOLE BIOGARAN G Esomeprazole (magnesium dihydrate) - 20mg 20mg Capsule, gastro-resistant 493,190 L.L
    3
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025